BTK Inhibitor Effective in Patients With Progressive, High-Risk CLL

EHA 2020: Study examined the effectiveness of brutons tyrosine kinase inhibitors for treating relapsed/refractory chronic lymphocytic leukemia after treament with venetoclax.